EB-003
Difficult-to-Treat Mental Health Disorders (PTSD, Treatment-Resistant Depression, Generalized Anxiety)
Key Facts
About Enveric Biosciences
Enveric Biosciences is a development-stage biotech focused on creating novel small-molecule therapeutics that promote neuroplasticity for treating mental health disorders, without inducing hallucinations. Its core strategy is powered by The Psybrary™, a proprietary platform used to generate and screen hundreds of novel compounds, leading to a robust IP portfolio. The company's most advanced program, EB-003, is in late preclinical development, targeting a first-in-class, prescription-based model for difficult-to-treat conditions. Enveric's approach aims to overcome key barriers to adoption in the psychedelic-inspired therapeutic space by developing drugs suitable for conventional clinical use.
View full company profile